SEAL BEACH, Calif--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, has appointed Darlene Romine as senior vice president of sales and market access and member of the company’s Executive Committee. Darlene brings to Dendreon more than 30 years of experience leading sales, market access and other commercial functions at leading pharmaceutical companies.
“Darlene is a proven high performer with a track record of growing complex specialty brands in highly competitive markets,” said Jason O’Neill, chief executive officer of Dendreon. “Her background and expertise building commercial organizations makes her an ideal fit as we accelerate the growth of PROVENGE® (sipuleucel-T) and execute Dendreon’s long-term vision of becoming a multi-product, multi-market company.”
Darlene has led sales, market access and commercial functions at specialty pharmaceutical companies, including Johnson & Johnson, Biogen and Mallinckrodt Pharmaceuticals. She was responsible for launching Avonex and Tysabri at Biogen. Avonex was the #1 prescribed multiple sclerosis medication during her six-year tenure and grew to over $1 billion in sales. At Mallinckrodt Pharmaceuticals, Darlene was responsible for growing the company’s neurology business by more than 500% from 2012 to 2013 and the company’s rheumatology business by more than 600% from 2013 to 2018.
“I am thrilled to join Dendreon at this critical juncture in the company’s transition into a global player in the prostate cancer space,” Darlene said. “I look forward to sharing my experience leading successful commercial organizations to improve access to PROVENGE for men with advanced prostate cancer who need it.”
Darlene holds a B.A. and a B.S. in education from Appalachian State University and was in the Advanced Management Program at the Kellogg School of Management at Northwestern University.
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of treatments that harness the power of the immune system to extend life. Dendreon’s flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Nearly 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Dendreon is headquartered in Seal Beach, Calif. For more information, please visit www.dendreon.com.